Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion‐weighted MRI
Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion‐weighted MRI
复制标题
DOI：
10.1212/wnl.43.2.397
复制
发表时间：
1993-02
期刊：
影响因子：
9.9
通讯作者：
K. Minematsu;M. Fisher;Liming Li;Michael A. Davis;A. Knapp;R. Cotter;R. McBurney;C. Sotak
中科院分区：
文献类型：
--
作者：
K. Minematsu;M. Fisher;Liming Li;Michael A. Davis;A. Knapp;R. Cotter;R. McBurney;C. Sotak
我们使用弥散加权磁共振成像(DWI)来确定大鼠大脑中动脉永久性闭塞后前3小时内的局灶性脑缺血区域。在脑缺血开始后30分钟使用弥散加权成像，就有可能确定未经治疗的动物的大脑区域在接下来的24小时内进展为脑梗塞，如尸检评估所证明的那样。DWT研究显示，非竞争性N-甲基-D-天冬氨酸受体拮抗剂CNS 1102在缺血后15分钟给药，在缺血的最初3小时内，对皮层和尾壳核区域都有保护作用。尽管在接下来的21小时内，少数血浆药物水平较低的动物在3小时内的治疗效果有所减弱，但尸检研究表明，随着治疗的进行，梗塞组织的总体积减少了66%，并证实了弥散加权成像的结果。在类似时间获得的T2加权MRT显示很少或没有异常。这些结果表明，弥散加权成像提供了一种灵敏的在体测量局灶性脑缺血损伤的方法，并可以评估细胞保护治疗的有益效果。弥散加权成像可能有助于对人类中风患者的早期评估，并在临床环境中监测脑保护治疗的效果。
We employed diffusion-weighted MRI (DWI) to identify regions of focal brain ischemia during the first 3 hours after permanent occlusion of the middle cerebral artery in rats. Using DWI as early as 30 minutes after the onset of ischemia, it was possible to identify the areas of brain destined to progress to infarction over the next 24 hours in untreated animals, as demonstrated by postmortem evaluation. DWT studies revealed the cerebroprotective effects of a noncompetitive N-methyl-D-aspartate receptor antagonist, CNS 1102, administered 15 minutes postocclusion, both on the cortical and caudoputaminal regions during the initial 3 hours of ischemia. Although the treatment effect lessened over the next 21 hours in a few animals with lower plasma drug levels at 3 hours, postmortem studies demonstrated a 66% reduction in the total volume of infarcted tissue with the treatment and confirmed the DWI results. T2-weighted MRT obtained at similar times revealed little or no abnormality. These results suggest that DWI provides a sensitive in vivo measure of focal cerebral ischemic injury and can assess the beneficial effects of cytoprotective therapy. DWI may be useful in the early evaluation of human stroke patients and in monitoring the effects of cerebroprotective therapies in the clinical setting.